The neuroprotective effect of doxycycline on neurodegenerative diseases
Abstract
Neurodegenerative diseases (NDs) are a group of chronic, progressive disorders characterized by the gradual loss of neurons that affect specific regions of the brain, which leads to deficits in specific functions (e.g., memory, movement, cognition). The mechanism that drives chronic progression of NDs remains elusive. Among the proposed underlying pathophysiological mechanisms, aggregation and accumulation of misfolded proteins and neuroinflammation have been credited to contribute to extensive neural loss. Therapeutic agents that confer neuroprotection by downregulating these shared characteristics could therefore have beneficial effects on a wide range of NDs. In this regard, a commonly used antibiotic, doxycycline (Doxy), has been shown to reduce the progression and severity of disease in different experimental models of neurodegeneration by counteracting these common features. This review will focus on the effects reported for Doxy regarding its neuroprotective properties, the "off-target" effects, thereby supporting its evaluation as a new therapeutic approach for diseases associated with a neurodegeneration.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Beta-lactams (cephalosporin antibiotics) have been shown to be effective in the treatment and alleviation of ND symptoms and in the treatment of experimentally induced neurological disorders such as PD, AD, ALS, traumatic brain injury, epilepsy, cerebral ischemia, and neuropathy.
“In particular, beta-lactams (cephalosporin antibiotics) have been shown to be effective in the treatment and alleviation of ND symptoms and in the treatment of experimentally induced neurological disorders such as PD, AD, ALS, traumatic brain injury (TBI), epilepsy, cerebral ischemia, and neuropathy (84, 117, 118).”
From Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis (2023) · cites this paper as [117]
Cites
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323 · see citing works
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,412 · see citing works
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · see citing works
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · see citing works
Neuropathology of Parkinson's Disease
Forno, L. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,556 · see citing works
Role of neuroinflammation in neurodegenerative diseases (Review)
Chen, W., Zhang, X., & Huang, W. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4948 · Cited by 933 · see citing works
Neurodegenerative Diseases and Prions
Prusiner, S. B. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105173442006 · Cited by 767 · see citing works
Inflammatory processes in Alzheimer's disease
McGeer, E. G., & McGeer, P. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00124-6 · Cited by 473 · see citing works
The history of the tetracyclines
Nelson, M. L., & Levy, S. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06354.x · Cited by 462 · see citing works
Protein Misfolding and Neurodegeneration
Soto, C. A., & Estrada, L. D. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.56 · Cited by 352 · see citing works
Transmissible spongiform encephalopathies
Collins, S. J., Lawson, V., & Masters, C. L. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15171-9 · Cited by 341 · see citing works
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 310 · see citing works
The molecular basis of neurodegeneration in multiple sclerosis
Lassmann, H., & van Horssen, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.004 · Cited by 296 · see citing works
Molecular pathogenesis of Parkinson's disease
Gandhi, S., & Wood, N. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi308 · Cited by 251 · see citing works
Anti‐amyloidogenic activity of tetracyclines: studies in vitro
Forloni, G., Colombo, L., Girola, L., Tagliavini, F., & Salmona, M. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02380-2 · Cited by 242 · see citing works
Neuroprotection by tetracyclines
Domercq, M., & Matute, C. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.10.001 · Cited by 205 · see citing works
Haı̈k, S., Marcon, G., Mallet, A., Tettamanti, M., Welaratne, A., Giaccone, G., Azimi, S., Pietrini, V., Fabreguettes, J., Imperiale, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70307-7 · Cited by 202 · see citing works
The Brain as a Target for Inflammatory Processes and Neuroprotective Strategies
Skaper, S. D. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1403.002 · Cited by 191 · see citing works
Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease
Gustot, A., Gallea, J. I., Sarroukh, R., Celej, M. S., Ruysschaert, J., & Raussens, V. (2015) · Biochemical Journal · doi:10.1042/bj20150617 · Cited by 183 · see citing works
Doxycycline Alters Metabolism and Proliferation of Human Cell Lines
Ahler, E., Sullivan, W. J., Cass, A. A., Braas, D., York, A. G., Bensinger, S. J., Graeber, T. G., & Christofk, H. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064561 · Cited by 170 · see citing works
Doxycycline Suppresses Microglial Activation by Inhibiting the P38 MAPK and NF-KB Signaling Pathways
Santa-Cecília, F. V., Socias, B., Ouidja, M. O., Sepulveda-Diaz, J. E., Acuña, L., Silva, R. L., Michel, P. P., Del-Bel, E., Cunha, T. M., & Raisman-Vozari, R. (2016) · Neurotoxicity Research · doi:10.1007/s12640-015-9592-2 · Cited by 165 · see citing works
Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162 · see citing works
Self-citationNewman, T. A. (2001) · Brain · doi:10.1093/brain/124.11.2203 · Cited by 143 · see citing works
Anti‐Inflammatory Properties of Low and High Doxycycline Doses: An In Vitro Study
Caprio, R. D., Lembo, S., Costanzo, L. D., Balato, A., & Monfrecola, G. (2015) · Mediators of Inflammation · doi:10.1155/2015/329418 · Cited by 138 · see citing works
Doxycycline restrains glia and confers neuroprotection in a 6‐OHDA Parkinson model
Lazzarini, M., Martin, S., Mitkovski, M., Raisman‐Vozari, R., Stühmer, W., & Bel, E. D. (2013) · Glia · doi:10.1002/glia.22496 · Cited by 119 · see citing works
Self-citationGonzález-Lizárraga, F., Socías, S. B., Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Binolfi, A., Sepúlveda-Díaz, J. E., Del-Bel, E., Fernandez, C. O., Papy-Garcia, D., et al. (2017) · Scientific Reports · doi:10.1038/srep41755 · Cited by 119 · see citing works
Self-citationThe Efficacy of Tetracyclines in Peripheral and Intracerebral Prion Infection
Luigi, A. D., Colombo, L., Diomede, L., Capobianco, R., Mangieri, M., Miccolo, C., Limido, L., Forloni, G., Tagliavini, F., & Salmona, M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001888 · Cited by 116 · see citing works
Diomede, L., Cassata, G., Fiordaliso, F., Salio, M., Ami, D., Natalello, A., Doglia, S. M., Luigi, A. D., & Salmona, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.002 · Cited by 114 · see citing works
Doxycycline in early CJD: a double-blinded randomised phase II and observational study
Varges, D., Manthey, H. G., Heinemann, U., Ponto, C., Schmitz, M., Schulz‐Schaeffer, W., Krasnianski, A., Breithaupt, M., Fincke, F., Kramer, K., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313541 · Cited by 106 · see citing works
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
Bortolanza, M., Nascimento, G. C., Socías, S. B., Ploper, D., Chehín, R. N., Raisman‐Vozari, R., & Bel, E. A. D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1913-1 · Cited by 105 · see citing works
Self-citationGolub, L. M., Elburki, M. S., Walker, C., RYAN, M. E., Sorsa, T. A., Tenenbaum, H. C., Goldberg, M. B., Wolff, M. S., & Gu, Y. (2016) · International Dental Journal · doi:10.1111/idj.12221 · Cited by 87 · see citing works
Cho, Y., Son, H. J., Kim, E.-M., Choi, J. H., Kim, S. T., Ji, I. J., Choi, D. H., Joh, T. H., Kim, Y. S., & Hwang, O. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9078-1 · Cited by 85 · see citing works
Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis
Minagar, A., Alexander, J. S., Schwendimann, R. N., Kelley, R. E., Gonzalez‐Toledo, E., Jimenez, J. J., Mauro, L., Jy, W., & Smith, S. J. (2007) · Archives of Neurology · doi:10.1001/archneurol.2007.41 · Cited by 84 · see citing works
Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models
Balducci, C., Santamaria, G., Vitola, P. L., Brandi, E., Grandi, F., Viscomi, A. R., Beeg, M., Gobbi, M., Salmona, M., Ottonello, S., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.002 · Cited by 81 · see citing works
Costa, A. R., Speretta, E., Crowther, D. C., & Cardoso, I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274548 · Cited by 79 · see citing works
Noble, W. J., Garwood, C. J., & Hanger, D. P. (2009) · Prion · doi:10.4161/pri.3.2.8820 · Cited by 67 · see citing works
Lucchetti, J., Fracasso, C., Balducci, C., Passoni, A., Forloni, G., Salmona, M., & Gobbi, M. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252064 · Cited by 67 · see citing works
Keijmel, S. P., Delsing, C. E., Bleijenberg, G., van der Meer, J. W. M., Donders, R. T., de Jager-Leclercq, M. G. L., Kampschreur, L. M., van den Berg, M., Sprong, T., Nabuurs-Franssen, M. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix013 · Cited by 65 · see citing works
Chui, D., Tabira, T., Izumi, S., Koya, G., & Ogata, J. (1994) · PubMed Central · Cited by 63 · see citing works
Tetracyclines and Prion Infectivity
Forloni, G., Salmona, M., Marcon, G., & Tagliavini, F. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/1871526510909010023 · Cited by 62 · see citing works
Forloni, G., Tettamanti, M., Lucca, U., Albanese, Y., Quaglio, E., Chiesa, R., Erbetta, A., Villani, F. S., Redaelli, V., Tagliavini, F., et al. (2015) · Prion · doi:10.1080/19336896.2015.1027857 · Cited by 59 · see citing works
Aggregopathy in Neurodegenerative Diseases: Mechanisms and Therapeutic Implication
Dohm, C. P., Kermer, P., & Bähr, M. (2008) · Neurodegenerative Diseases · doi:10.1159/000119459 · Cited by 54 · see citing works
Socías, S. B., González‐Lizárraga, F., Ávila, C. L., Vera, C., Acuña, L., Sepulveda-Diaz, J. E., Bel, E. A. D., Raisman‐Vozari, R., & Chehín, R. N. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.002 · Cited by 54 · see citing works
Self-citationStarckx, S., den Steen, P. E. V., Verbeek, R., van Noort, J., & Opdenakker, G. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00217-0 · Cited by 48 · see citing works
Forloni, G., Artuso, V., Roiter, I., et al. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660173 · Cited by 41 · see citing works
Schmitz, M., Cramm, M., Llorens, F., et al. (2016) · Scientific Reports · doi:10.1038/srep28711 · Cited by 38 · see citing works
Dendritic Cells as an Alternate Approach for Treatment of Neurodegenerative Disorders
Brezováková, V., Valachova, B., Hanes, J., Novák, M., & Jadhav, S. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0598-1 · Cited by 28 · see citing works
A study on the protective role of doxycycline upon dopaminergic neuron of LPS-PD rat model rat.
Gb, Z., Yh, F., Pq, W., Jh, S., Wang, P., & Wang, S.-A. (2015) · PubMed · Cited by 21 · see citing works
Imaging multiple sclerosis and other neurodegenerative diseases
Inglese, M., & Petracca, M. (2013) · Prion · doi:10.4161/pri.22650 · Cited by 21 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Doxycycline Inhibits α-Synuclein-Associated Pathologies in Vitro and in Vivo
Dominguez-Meijide, A., Parrales, V., Vasili, E., González-Lizárraga, F., König, A., Lázaro, D. F., Lannuzel, A., Haik, S., Del Bel, E., Chehín, R., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105256 · Cited by 81 · see citing works
Self-citationHong, D., Zhang, C., Wu, W., Lu, X., & Zhang, L. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1133546 · Cited by 38 · see citing works
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36 · see citing works
Bortolanza, M., do Nascimento, G. C., Raisman‐Vozari, R., & Del‐Bel, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15439 · Cited by 33 · see citing works
Moszczynski, A. J., Harvey, M., Fulcher, N., de Oliveira, C., McCunn, P., Donison, N., Bartha, R., Schmid, S., Strong, M. J., & Volkening, K. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0816-1 · Cited by 15 · see citing works
- Authors
- Santa-Cecília, F. V., Leite, C. A., Del-Bel, E., & Raisman-Vozari, R.
- Affiliations
- Instituto Butantan (BR)
- AC Camargo Hospital (BR)
- ORCID
- Leite, Caio Abner
- Venue
- Neurotoxicity Research
- Published
- 2019-02-23
- Volume
- 35
- Issue
- 4
- Pages
- 981-986
- ISSN
- 1029-8428 (ISSN-L)
- 1476-3524
- OpenAlex
- W2915676720
- Cited by
- 73
- References
- 49
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 12 · 2023: 11 · 2022: 15 · 2021: 8 · 2020: 8 · 2019: 3
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neurotoxicity Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
- Keywords
- doxycycline, neuroprotection, neurodegenerative diseases, neuroinflammation, protein aggregation, off-target effects, antibiotic repurposing, neurodegeneration therapy
- MeSH terms
- Animals, Brain, Clinical Trials as Topic, Doxycycline, Encephalitis, Humans, Neurons, Neuroprotective Agents, Neurodegenerative Diseases, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
